Valo Therapeutics Overview

  • Status
  • Private
  • Employees
  • 7
  • Latest Deal Type
  • Series A
  • (Upcoming)
  • Investors
  • 2

Valo Therapeutics General Information


Developer of novel cancer immunotherapy designed to transform the lives of millions of cancer patients. The company's immunotherapy adsorb tumor-specific peptides to the surface of an oncolytic virus, thereby eliciting an enhanced adaptive immune response against the tumor and use immunogenic viruses as active carriers of tumor-specific peptides to direct the immune system to specifically target and kill cancer cells, enabling patient to get proper treatment for cancer in different stages of the same tumor.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Industries
Other Healthcare Services
Other Healthcare Technology Systems
Primary Office
  • Viikinkaari 6
  • 00790 Helsinki
  • Finland

Valo Therapeutics Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Valo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series A) Upcoming Generating Revenue
4. Angel (individual) 06-Feb-2020 00.000 000.00 Completed Generating Revenue
3. Angel (individual) 20-Jun-2018 00.000 00.00 000.00 Completed Generating Revenue
2. Debt - General 04-Jul-2017 $4.6M $7.96M Completed Generating Revenue
1. Early Stage VC 31-Jan-2017 $3.36M $3.36M 000.00 Completed Generating Revenue
To view Valo Therapeutics’s complete valuation and funding history, request access »

Valo Therapeutics Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 00,000 000.00 000.00 00 000.00 00.000
To view Valo Therapeutics’s complete cap table history, request access »

Valo Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Michael Stein Ph.D Chief Executive Officer & Co-Chairman
Paul Higham Chief Executive Officer
Scott Cuthill Ph.D Chief Business Officer
Vincenzo Cerullo Scientific Founder & Board Member
To view Valo Therapeutics’s complete executive team members history, request access »

Valo Therapeutics Board Members (6)

Name Representing Role Since
Mai-Britt Zocca Ph.D Valo Therapeutics Board Member 000 0000
Matti Hautsalo Self Co-Chairman 000 0000
Michael Stein Ph.D Valo Therapeutics Chief Executive Officer & Co-Chairman 000 0000
Milla Koistinaho Ph.D Self Board Member 000 0000
Paul Porter Valo Therapeutics Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Valo Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Valo Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Glenmarie Estates Limited Partner Minority 000 0000 000000 0
University of Helsinki Endowment Limited Partner Minority 000 0000 000000 0
To view Valo Therapeutics’s complete investors history, request access »